Telix Pharmaceuticals (NASDAQ:TLX) Given New $20.00 Price Target at HC Wainwright

Key Points

• HC Wainwright lowered the price target for Telix Pharmaceuticals from $23.00 to $20.00 while maintaining a "buy" rating, indicating a potential upside of 107.04% from the current price.
• Several other analysts have given the stock an average rating of "Moderate Buy", with one Hold rating and price targets varying from $20.00 to $22.00.
• The stock saw a 4.0% increase during trading, reaching $9.66, with a current 52-week range from $8.93 to $30.36.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) had its price target lowered by research analysts at HC Wainwright from $23.00 to $20.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 107.04% from the company's current price.

A number of other equities analysts also recently commented on the stock. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Wedbush reiterated an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $21.33.

Telix Pharmaceuticals Stock Up 4.0%

TLX stock traded up $0.37 during trading on Wednesday, reaching $9.66. 105,770 shares of the stock traded hands, compared to its average volume of 62,514. The business's 50 day moving average price is $12.95 and its 200-day moving average price is $15.63. Telix Pharmaceuticals has a 52-week low of $8.93 and a 52-week high of $30.36. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Private Advisor Group LLC bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter worth about $170,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals in the second quarter worth approximately $213,000. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals in the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals in the second quarter worth approximately $297,000. Finally, ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals in the first quarter worth approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.